Interferon Regulatory Factor 4 (IRF-4) is a member of the interferon regulatory factor (IRF) family of transcription factors. IRFs play critical roles in the regulation of genes involved in immune responses, cell growth, and hematopoietic development. IRF-4, in particular, is essential for the differentiation and function of various immune cells, especially B cells, T cells, and dendritic cells. The protein is induced by signals that lead to lymphocyte activation, and it subsequently regulates the expression of genes that are vital for immune cell function. Moreover, IRF-4 is involved in the regulation of cytokine gene expression and has been implicated in controlling the balance between Th1 and Th2 cell responses. Given its central role in immune system regulation, the precise modulation of IRF-4 activity is of paramount importance for maintaining immune homeostasis and ensuring appropriate responses to pathogens.
IRF-4 inhibitors are a class of chemical compounds designed to target and modulate the activity or expression of IRF-4. These inhibitors can function through diverse mechanisms. Some might bind directly to IRF-4, blocking its DNA-binding domain and thereby preventing it from modulating the transcription of its target genes. Others might interfere with the interaction between IRF-4 and its co-factors or partner proteins, disrupting the formation of functional transcriptional complexes. Additionally, some inhibitors might target the signaling pathways that regulate the expression or post-translational modifications of IRF-4, leading to altered levels or activity of the transcription factor.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide has been shown to degrade IRF-4 via the cereblon pathway, leading to reduced protein expression in multiple myeloma cells. | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $100.00 $143.00 $312.00 $468.00 $1248.00 $1997.00 | 1 | |
Similar to lenalidomide, pomalidomide induces the degradation of IRF-4 in multiple myeloma cells through the cereblon pathway. | ||||||
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
I-BET151, a BET bromodomain inhibitor, suppresses IRF-4 transcription, leading to reduced expression in multiple myeloma cells. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1, a BET bromodomain inhibitor, down-regulates IRF-4 transcription and reduces its expression in hematologic malignancies. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
All-trans retinoic acid (ATRA) can modulate the differentiation of immune cells, potentially suppressing IRF-4 expression in certain contexts. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK1/2 inhibitor, can suppress IRF-4 expression in JAK-STAT signaling-associated conditions. | ||||||
AZD1480 | 935666-88-9 | sc-364735 sc-364735A | 5 mg 50 mg | $124.00 $1072.00 | 11 | |
AZD1480, a JAK1/2 inhibitor, can down-regulate IRF-4 in conditions with aberrant JAK-STAT signaling. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib targets BTK and could indirectly reduce IRF-4 expression in B-cell malignancies. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a tyrosine kinase inhibitor, can impact various signaling pathways and may reduce IRF-4 expression in certain contexts. | ||||||